Type 2 Diabetes

RIP140 agonist advances into studies for treatment of obesity, type 2 diabetes

Published in Obesity and Diabetes Week, September 26th, 2005

CytRx Corp. (CYTR) announced that it has determined to advance a small interfering RNA (siRNA) against RIP140 into animal studies for the treatment of type 2 diabetes and obesity.

In work conducted independently by Michael P. Czech, PhD, professor and chair of molecular medicine at the University of Massachusetts Medical School (UMMS) and Dr. Malcolm Parker of the Imperial College London, these investigators have shown that suppression of RIP140 by gene-deletion or siRNA results in the acceleration of fat burning in animals and fat cells, respectively.

In a paper published in the Proceedings of the National Academy of Science in 2004 by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry